Antibodies, Monoclonal - Research News and Information

Wednesday, January 07, 2009

The antitumor activity of an anti-CD54 antibody in SCID mice xenografted with human breast, prostate, non-small cell lung, and pancreatic tumor cell lines.

13 Nov 2008 We have previously described the development and testing of a monoclonal anti-human CD54 antibody (UV3) in SCID mice xenografted with human multiple myeloma, lymphoma, and melanoma cell lines. In all 3 cases, UV3 was highly effective at slowing the ... Read more...

[Extranodal marginal zone lymphoma of the ocular adnexa]

Nov 2008 INTRODUCTION: Lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) is among the most common malignant lymphomas of the ocular adnexa and it furthermore shows an increasing incidence. The disease is most often localized and indolent of ... Read more...

Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies.

30 Oct 2008 Overproduction of plasma cell-derived monoclonal free kappa or lambda immunoglobulin light chains (FLCs) is a hallmark of multiple myeloma, AL amyloidosis, and light chain deposition disease. Because these components serve as unique cellular and ... Read more...

Learn Faster Today      Improve your study skills

Latest indexed articles for 'Antibodies, Monoclonal'

These are the very latest articles for this heading:

• The antitumor activity of an anti-CD54 antibody in SCID mice xenografted with human breast, prostate, non-small cell lung, and pancreatic tumor cell lines. 13 Nov 2008
• [Extranodal marginal zone lymphoma of the ocular adnexa] Nov 2008
• Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies. 30 Oct 2008
• When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step? 30 Oct 2008
• Anti-tumour necrosis factor alpha therapy modulates ghrelin in patients with severe rheumatoid arthritis. 30 Oct 2008
• Successful treatment of psoriatic arthritis with rituximab. 30 Oct 2008
• Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate. 30 Oct 2008
• Balancing immunity and immunosuppression: vaccinating patients receiving treatment with efalizumab. 30 Oct 2008
• Trial watch: novel biologic for psoriasis shows superiority over current best-seller. 30 Oct 2008
• Deal watch: Ablynx and Merck Serono collaborate on next-generation antibody products. 30 Oct 2008
• Cystoid macular edema secondary to albumin-bound paclitaxel therapy. 30 Oct 2008
• Identification of an expressed truncated form of CD200, CD200tr, which is a physiologic antagonist of CD200-induced suppression. 25 Oct 2008
• K-ras mutations and benefit from cetuximab in advanced colorectal cancer. 21 Oct 2008
• Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. 21 Oct 2008
• Case records of the Massachusetts General Hospital. Case 33-2008. A 63-year-old woman with dyspnea on exertion. 21 Oct 2008
• Targeting EGFR in colorectal cancer. 21 Oct 2008
• Multiple lessons for multiple sclerosis. 21 Oct 2008
• Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. 19 Oct 2008
• Disseminated histoplasmosis associated with the treatment of rheumatoid arthritis with anticytokine therapy. 19 Oct 2008
• Desensitization during renal transplantation. 14 Oct 2008

See a longer list of these articles.

Technical information about 'Antibodies, Monoclonal'

Definition: Antibodies produced by clones of cells such as those isolated after hybridization of activated B LYMPHOCYTES with neoplastic cells. These hybrids are often referred to as HYBRIDOMAS.

Registry Number: 0

Descriptor UI: D000911

Alternative terms: Antibodies, Monoclonal; Monoclonal Antibodies;

Related Mesh Headings: Hybridomas;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; biosynthesis; blood; cerebrospinal fluid; classification; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacology; physiology; poisoning; radiation effects; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; pharmacokinetics;

Pharmacological Action: Immunologic Factors;

Tree Number: D12.776.124.486.485.114.224; D12.776.124.790.651.114.224; D12.776.377.715.548.114.224;

History Note: 82

Technical Notes: do not coordinate with ANTIBODY FORMATION for biosyn; ANTIBODY-TOXIN CONJUGATES is available as a toxin carrier: see note there